Peyronie's Disease (Stable Phase)
Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for Peyronie's disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for Peyronie's is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Only case-report-level evidence exists; there are no randomized controlled trials. Evidence-based options for stable-phase Peyronie's (plaque present at least 12 months without progression) include intralesional verapamil, intralesional collagenase clostridium histolyticum (FDA-approved as Xiaflex), mechanical traction devices, and surgical correction (plication or grafting with or without prosthesis placement) for refractory or severe deformity. Active-phase disease requires symptom-targeted therapy, not direct plaque intervention.
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment in a highly vascular area
- Bruising and tenderness of penile or pubic skin for 5 to 10 days
- Local skin infection, hematoma, or Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Worsening of plaque pain or new pain on erection
- Cosmetic scarring at bite sites
- Delay or replacement of effective therapies (intralesional collagenase, traction, surgery)
- Wer dies nicht in Betracht ziehen sollte
- Patients in the acute / active phase (less than 12 months from onset, ongoing plaque progression, painful erections)
- Patients with active genital infection, STI, or balanitis
- Patients requiring penile prosthesis for erectile dysfunction
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients with an indwelling urethral catheter
- Patients who have not been evaluated by a urologist
- Was Sie Ihren Kliniker fragen sollten
- Has my plaque been stable for at least 12 months without progression (true stable phase)?
- Have I been offered intralesional collagenase (Xiaflex), intralesional verapamil, or mechanical traction?
- Am I a candidate for surgical correction (plication, grafting, or penile prosthesis)?
- What is the realistic effect size with leech therapy versus proven interventions?
- Where will leeches be placed, and how will my urethra and glans be protected?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- Wann dringende medizinische Versorgung suchen
- Sustained painful erection lasting more than 4 hours (priapism — urology emergency)
- Sudden new severe penile pain, hematoma, or hard mass
- Inability to urinate or new blood in urine
- Spreading redness, pus, or warmth on the penis or pubic area
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is not FDA-cleared for Peyronie's disease.
- Case reports do NOT establish efficacy versus intralesional collagenase, verapamil, traction, or surgical correction.
- Mechanism rationale (antifibrotic salivary peptides) does NOT establish clinical efficacy.
- Leech therapy is not a substitute for urologic evaluation and proven Peyronie's therapies.
- Active-phase Peyronie's should NOT be treated with leech therapy — symptom-directed care is appropriate first.
Sicherheits-Querverweise
Clinical Profile
- Category
- urogenital
- ICD-10
- N48.6
- Safety tier
- high
Evidence Summary
No controlled clinical trial of leech therapy for Peyronie's disease has been published; any use is investigational and mechanistic only, theorizing an antifibrotic action of leech salivary peptides on tunica albuginea fibrosis. Evidence is too preliminary for any quantitative effect-size estimate. Standard management (intralesional verapamil, intralesional collagenase clostridium histolyticum, mechanical traction, surgical plication or grafting) remains the mainstay. ASH position: only as exploratory adjunct under urology supervision in stable-phase disease (>12 months from onset, no recent plaque progression). Acute-phase Peyronie's (active inflammation, pain on erection) is a contraindication.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Bahmani M et al. (2014)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Acute-phase Peyronie's with active inflammation
- Erectile dysfunction requiring penile prosthesis
- Active genital infection or STI
Related Conditions
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.
Chronic Prostatitis / Chronic Pelvic Pain Syndrome (Extended Protocol)
Investigational extended-protocol adjunct for NIH Category III chronic prostatitis/CPPS; small case series only; UPOINT-directed therapy remains primary.
Interstitial Cystitis / Bladder Pain Syndrome (Investigational)
Highly investigational adjunct for IC/BPS refractory to conventional therapy; case reports only; AUA-guideline stepwise therapy remains primary.
Peyronie's Disease (Extended Investigational Adjunct)
Highly investigational extended-protocol adjunct for stable Peyronie's disease; case reports only; collagenase clostridium histolyticum and surgical correction remain primary.